- Home
- MNPR vs ITOS Comparison
MNPR vs ITOS Comparison
Compare MNPR & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- ITOS
- Stock Information
- Founded
- MNPR 2014
- ITOS 2011
- Country
- MNPR United States
- ITOS United States
- Employees
- MNPR N/A
- ITOS N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNPR Health Care
- ITOS Health Care
- Exchange
- MNPR Nasdaq
- ITOS Nasdaq
- Market Cap
- MNPR 249.5M
- ITOS 270.7M
- IPO Year
- MNPR 2019
- ITOS 2020
- Fundamental
- Price
- MNPR $31.73
- ITOS $10.02
- Analyst Decision
- MNPR Strong Buy
- ITOS Hold
- Analyst Count
- MNPR 5
- ITOS 6
- Target Price
- MNPR $59.50
- ITOS $10.60
- AVG Volume (30 Days)
- MNPR 18.2K
- ITOS 2.6M
- Earning Date
- MNPR 05-13-2025
- ITOS 04-28-2025
- Dividend Yield
- MNPR N/A
- ITOS N/A
- EPS Growth
- MNPR N/A
- ITOS N/A
- EPS
- MNPR N/A
- ITOS N/A
- Revenue
- MNPR N/A
- ITOS $35,000,000.00
- Revenue This Year
- MNPR N/A
- ITOS N/A
- Revenue Next Year
- MNPR N/A
- ITOS $31.74
- P/E Ratio
- MNPR N/A
- ITOS N/A
- Revenue Growth
- MNPR N/A
- ITOS 177.89
- 52 Week Low
- MNPR $1.72
- ITOS $4.80
- 52 Week High
- MNPR $54.30
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- MNPR 37.28
- ITOS 73.75
- Support Level
- MNPR $34.02
- ITOS $8.30
- Resistance Level
- MNPR $36.82
- ITOS $11.35
- Average True Range (ATR)
- MNPR 3.54
- ITOS 0.53
- MACD
- MNPR -0.71
- ITOS 0.22
- Stochastic Oscillator
- MNPR 27.91
- ITOS 71.15
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.